PA
IMRX icon

Perceptive Advisors’s Immuneering IMRX Stock Holding History

Perceptive Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-681,051
Closed -$4.41M – 115
2022
Q1 		$4.41M Hold
681,051
– – 0.09% 111
2021
Q4 		$11M Hold
681,051
– – 0.17% 88
2021
Q3 		$18.1M Buy
+681,051
New +$18.3M 0.26% 72

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors's IMRX Position: Q2 2022 in Review

Perceptive Advisors sold out of Immuneering (IMRX) in Q2 2022, closing a stake of 681,051 shares — an estimated $4.41M sold.

Perceptive Advisors first reported a position in IMRX in Q3 2021 and held it in 3 quarters. The position peaked at $18.1M in Q3 2021. 37 funds tracked by Wall St. Rank hold IMRX as of Q2 2022.

  • Perceptive Advisors reported no remaining Immuneering position as of Q2 2022 after selling out during the quarter.
  • Perceptive Advisors sold 681,051 Immuneering shares in Q2 2022, an estimated $4.41M.
  • Perceptive Advisors first reported a position in Immuneering in Q3 2021 and held it in 3 quarters.
  • Perceptive Advisors's Immuneering position peaked at $18.1M in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Immuneering as of Q2 2022.

Based on Perceptive Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.